Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 1
1995 3
1996 2
1997 1
1998 1
2001 1
2002 2
2003 1
2004 1
2006 3
2007 2
2009 1
2010 2
2011 4
2012 3
2014 3
2015 6
2016 1
2018 3
2020 4
2021 1
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

44 results
Results by year
Filters applied: . Clear all
Page 1
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X, Chan HTC, Fisher H, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, French RR, Duriez PJ, Douglas LR, English V, Verbeek JS, White AL, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: mockridge ci. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. doi: 10.1016/j.ccell.2020.04.013. Epub 2020 May 21. Cancer Cell. 2020. PMID: 32442402 Free PMC article.
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Yeboah M, Papagregoriou C, Jones DC, Chan HTC, Hu G, McPartlan JS, Schiött T, Mattson U, Mockridge CI, Tornberg UC, Hambe B, Ljungars A, Mattsson M, Tews I, Glennie MJ, Thirdborough SM, Trowsdale J, Frendeus B, Chen J, Cragg MS, Roghanian A. Yeboah M, et al. Among authors: mockridge ci. JCI Insight. 2020 Sep 1;5(18):e141593. doi: 10.1172/jci.insight.141593. JCI Insight. 2020. PMID: 32870822 Free PMC article.
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, Mårtensson L, Kim J, Inzhelevskaya T, Penfold CA, Tutt AL, Mockridge CI, Chan HC, English V, French RF, Teige I, Al-Shamkhani A, Glennie MJ, Frendeus BL, Willoughby JE, Cragg MS. Griffiths J, et al. Among authors: mockridge ci. J Immunother Cancer. 2020 Dec;8(2):e001557. doi: 10.1136/jitc-2020-001557. J Immunother Cancer. 2020. PMID: 33428585 Free PMC article.
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Simpson AP, Roghanian A, Oldham RJ, Chan HTC, Penfold CA, Kim HJ, Inzhelevskaya T, Mockridge CI, Cox KL, Bogdanov YD, James S, Tutt AL, Rycroft D, Morley P, Dahal LN, Teige I, Frendeus B, Beers SA, Cragg MS. Simpson AP, et al. Among authors: mockridge ci. Cell Rep. 2022 Jul 19;40(3):111099. doi: 10.1016/j.celrep.2022.111099. Cell Rep. 2022. PMID: 35858562 Free article.
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL. Yu X, et al. Among authors: mockridge ci. Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22. Cancer Cell. 2018. PMID: 29576376 Free PMC article.
Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo.
Tipton TR, Mockridge CI, French RR, Tutt AL, Cragg MS, Beers SA. Tipton TR, et al. Among authors: mockridge ci. Blood. 2015 Dec 10;126(24):2643-5. doi: 10.1182/blood-2015-09-671339. Epub 2015 Oct 22. Blood. 2015. PMID: 26492935 Free article. No abstract available.
44 results